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Background: Baicalein, a natural flavonoid obtained from the Scutellaria baicalensis root, has been reported to
inhibit growth of human lung cancer. However, the detailed mechanism underlying this has not been well
elucidated.
Methods: Cell viability was measured using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
assays. Apoptosis was detected by flow cytometry analysis and caspase 3/7 assays. The expression of RUNX3 and
FOXO3a mRNA were measured by real time RT-PCR methods. Western blot analysis was performed to measure
the phosphorylation and protein expression of AMP-activated protein kinase alpha (AMPKα) and extracellular
signal-regulated kinase 1/2 (ERK1/2), runt-related transcription factor 3 (RUNX3) and forkhead box O3a (FOXO3a).
Silencing of FOXO3a and RUNX3 were performed by small interfering RNA (siRNA) methods. Exogenous expression
of FOXO3a or RUNX3 was carried out by electroporated transfection assays.
Results: We showed that baicalein significantly inhibited growth and induced apoptosis of non-small cell lung
cancer (NSCLC) cells in a time- and dose-dependent manner. Baicalein induced RUNX3 and FOXO3a protein expression,
and increased phosphorylation of AMPKα and ERK1/2. Moreover, the inhibitors of AMPK and MEK/ERK1/2 reversed the
effect of baicalein on RUNX3 and FOXO3a protein expression. Interestingly, while compound C had little effect on
blockade of baicalein-induced phosphorylation of ERK1/2, PD98059 significantly abrogated baicalein-induced
phosphorylation of AMPKα. Intriguingly, while silencing of RUNX3 abolished the effect of baicalein on expression
of FOXO3a and apoptosis, silencing of FOXO3a significantly attenuated baicalein-reduced cell proliferation. On the
contrary, overexpression of FOXO3a restored the effect of baicalein on cell growth inhibition in cells silencing of
endogenous FOXO3a gene and enhanced the effect of baicalein on RUNX3 protein expression. Finally, exogenous
expression of RUNX3 increased FOXO3a protein and strengthened baicalein-induced phosphorylation of ERK1/2.
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Conclusion: Collectively, our results show that baicalein inhibits growth and induces apoptosis of NSCLC cells through
AMPKα- and MEK/ERK1/2-mediated increase and interaction of FOXO3a and RUNX3 protein. The crosstalk between
AMPKα and MEK/ERK1/2 signaling pathways, and the reciprocal interplay of FOXO3a and RUNX3 converge on the
overall response of baicalein. This study reveals a novel mechanism for regulating FOXO3a and RUNX3 signaling axis
in response to baicalein and suggests a new strategy for NSCLC associated targeted therapy.
Keywords: Baicalein, NSCLC, RUNX3, FOXO3a, MEK/ERK1/2, AMPKαIntroduction
Lung cancer remains one of the leading causes of
cancer-related death in men and women worldwide [1].
Non-small cell lung cancer (NSCLC) is more common
and the majority of patients present with advanced stage
[2]. Emerging data demonstrate promising outcome of
other non-surgical treatment in patients with advanced
lung cancer. Traditional Chinese medicine (TCM) plays
an important role in protecting cancer patients against
suffering from other treatment related complications,
helping in supportive and palliative care by reducing
toxicity of conventional therapy and improving quality
of life [3-6]. However, the mechanisms by which TCM in
improving the therapeutic efficiency against the lung
malignancies remains poorly understood.
Phytochemicals are naturally occurring, plant-based
substances that have garnered attention for their anti-
cancer properties, both as therapeutics and components
of the diet for chemoprevention. One particularly
ubiquitous group of phytochemicals is the polyphenolic
flavonoids. Baicalein, a natural flavonoid obtained from
the Scutellaria baicalensis root, were showed to inhibit
proliferation of several malignant tumors including lung
cancer [7-10]. One study showed that the therapeutic
effects of baicalein are attributed to control proliferation,
metastasis and inflammatory microenvironment in
human lung cancer cells [7]. Multiple signaling pathways
and potential targets involved in the baicalein-suppressed
cancer cell growth, including lung, have been reported in
the past [7,9-11]. However, the underlying molecular
mechanisms associated with its efficacy in targeting lung
cancer are largely unknown.
Mammalian forkhead members of the class O (FOXO)
transcription factors, a superfamily of proteins are impli-
cated in the regulation of variety of biological functions,
such as apoptosis, cell cycle transitions, DNA repair,
metabolism, oxidative stress, and cell differentiation
[12]. In humans, four members of the FOXO transcrip-
tion factors (FOXO1, FOXO3a, FOXO4 and FOXO6)
have been found [13]; they share a high degree of
conserved 100-residue DNA-binding domain, so-called
forkhead domain in their DNA-binding area [14].
Among them, FOXO3a has been extensively studied as a
crucial protein. Previous studies showed that FOXO3aregulated expression of genes involved in apoptosis, cell
cycle arrest, oxidative stress resistance and was nega-
tively regulated by growth factors [15]. During tumor
development, inhibition of FOXO3a stimulated cell trans-
formation, tumor progression, and angiogenesis [16]. On
the contrary, overexpression of FOXO3a suppressed
cancer cell growth, modulated expression of downstream
effectors, induced apoptosis, and reduced tumor size
[17-19]. These results indicated a tumor suppressor role
of FOXO3a, which could be a potential target for the
treatment of cancers.
The runt-related transcription factors (RUNXs) belong
to a family of conserved proteins, which share the highly
homologous DNA-binding, N-terminal Runt domain
[20]. To date, three RUNX transcription factors, i.e.,
RUNX1, RUNX2 and RUNX3, have been identified.
Among these, RUNX3, the smallest member of RUNX
family, reported to be involved in various cancer processes,
such as cell growth, apoptosis, angiogenesis, and metastasis
[21]. Study demonstrated that RUNX3 is a tumor suppres-
sor gene, which is absent or mutated in several types of
cancers including lung due to hemizygous deletions or
epigenetic alterations [22]. One report found that RUNX3
inactivation is a crucial early step in the development of
lung malignancy [23].
In this study, we explore the potential mechanism by
which baicalein controls lung cancer cell proliferation.
Materials and methods
Reagents
Monoclonal antibodies against to total ERK1/2, AMPKα
and the phosphor-forms were purchased from Cell
Signaling Technology Inc. (Beverly, MA, USA). The
FOXO3a and RUNX3 antibodies were obtained from
Epitomics (Burlingame, CA, USA). PD98059 (MAPK
extracellular signaling-regulated kinase (ERK) kinase
(MEK)/ERK1/2 inhibitor) and compound C (inhibitor of
AMPK) were purchased from Merck Millipore (Billerica,
MA, USA), MTT powder was purchased from Sigma
Aldrich (St. Louis, MO, USA). FOXO3a and RUNX3 small
interfering RNAs (siRNAs) were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Baicalein was
purchased from Chengdu Must Bio-technology Company
(Chengdu, Sichuan, China). The drugs were freshly diluted
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applying to experiments.
Cell lines and cultures
Human lung adenocarcinoma cells (PC9, H1299, H1650,
A549, H358 and H1975) were obtained from the
Chinese Academy of Sciences Cell Bank of Type Culture
Collection (Shanghai, China) and the Cell Line Bank at the
Laboratory Animal Center of Sun Yat-sen University
(Guangzhou, China). The cells were cultured at 37°C in a
humidified atmosphere containing 5% CO2. The culture
medium consisted of RPMI 1640 medium obtained from
GIBCO, Life Technologies (Grand Island, NY, USA)
supplemented with 10% (v/v) heat-inactivated fetal bovine
serum (Thermo Fisher Scientific Inc, Waltham, MA, USA),
100 μg/ml streptomycin and 100 U/mL penicillin. When
cells reached 75% confluence, they were digested with
0.25% trypsin for passage for the following experiments.
Cell viability assay
We used 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-
zolium bromide (MTT) method to determine cell via-
bility as described previously [19]. Briefly, NSCLC
cells were harvested, counted and seeded into a 96-well
microtiterplate, 5 × 103 cells/well. The cells were treated
with increasing concentrations of baicalein for up to 72 h.
After incubation, 10 μL MTT solution (5 g/L) was
included to each well and cells were incubated at 37°C for
an additional 4 h, followed by removing the supernatant,
adding 150 μL solvent dimethyl sulfoxide (DMSO), and
oscillating for 10 min. Afterwards, absorbance at 570 nm
was determined through the use of ELISA reader (Perkin
Elmer, Victor X5, Waltham, MA, USA). Each experiment
was repeated three times. Cell viability (%) was calculated
as follows: (absorbance of test sample/absorbance of
control) × 100%.
Cell apoptosis assays
Annexin V-FITC/PI Apoptosis Detection Kit (BD
Biosciences, San Jose, CA, USA) was used to detect
cell apoptosis according to instructions from the
manufacturer. Briefly, after treated with baicalein for
24 h, the apoptotic cells were harvested by Trypsin
(no EDTA) and washed with phosphate-buffered saline
(PBS), then resuspended the cells in 500 μL binding
buffer, 5 μL Annexin V-FITC regent and 10 μL PI
regents and incubated for 5 min at room temperature
(RT) in the dark, followed by detecting cell apoptosis
by Flow cytometry (FC500, Beckman, USA).
Detection of caspase-3/7 activity
We examined the activity of caspase-3/7 using the
Caspase-Glo 3/7 Assay kit (Promega, Madison, WI, USA),
which based on the manufacturer’s instruction. Briefly,NSCLC cells were seeded in 96-well plates and treated
with or without baicalein for 48 h. Afterwards, the cells
were lysed and incubated with 100 μL of Apo-ONE
Caspase-3/7 reagent (substrate and buffer in the ratio
of 1:100). After 1 h incubation in the dark at RT, the
fluorescence of each well was measured at 485–520 nm by
reading in an Epoch microplate reader (Biotek Instruments;
Winooski, VT, USA).
Quantitative real-time PCR (qRT-PCR)
A quantitative real-time RT-PCR assay was developed
for the detection and quantification of RUNX3 and
FOXO3a transcripts using GAPDH as an endogenous
control. The primers used in this study were designed as
follows: RUNX3 forward 5’- 5′-TTATGAGGGGTGG
TTG-TATGTGGG-3′ and reverse 5′-AAAACAACC
AACACAAACACCTCC-3′ [24]. FOXO3a and GAPDH
(used as an internal control) used the following primers:
forward 5′-GCAAGCACAGAGTTGGATGA-3′ (F) and
reverse 5′-CAGGTCGTCCATGAGGTTTT -3′(R) for
FOXO3a [25] and forward 5’- AAGCCTGCCGGTGAC
TAAC -3’; reverse 5’- GCGCCCAATACGACCAAATC -3’
for GAPDH. Total RNA was extracted using the TRIzol
solution and the first-strand cDNA was synthesized from
total RNA (2 μg) by reverse transcription using oligo-dT
primers and Superscript II reverse transcriptase (Invitrogen,
Grand Island, NY, USA) according to the manufacturer’s
instructions. Quantitative real-time PCR was performed in
a 20 μL mixture containing 2 μL of the cDNA preparation,
10 μL 2X SYBR Green Premix ExTaq, and 10 μM pri-
mer on an ABI 7500 Real-Time PCR System (Applied
Biosystems, Grand Island, NY, USA). The PCR conditions
were as follows: 0.5 min at 95°C, followed by 40 cycles of
5 s at 95°C, and 34 s at 60°C. Each sample was tested in
triplicate. Threshold values were determined for each
sample/primer pair; the average and standard errors were
calculated. The relative expression levels of the target
genes RUNX3 and FOXO3a were normalized to that of
GAPDH. The data were analyzed using the comparative
threshold cycle (2−ΔΔCT) method.
Western blot analysis
The detailed method was based on previous report [19].
After measuring the protein concentrations using the
Bio-Rad protein method, whole cell lysates containing same
amount of protein were solubilized in 4× SDS-sample
buffer and separated on 10% SDS polyacrylamide gels.
Membranes (Millipore, Billerica, MA, USA) were incubated
with antibodies against ERK1/2, AMPKa, pERK1/2,
p-AMPKα, FOXO3a and RUNX3 (1:1000). The membranes
were washed and incubated with a secondary goat
antibody raised against rabbit IgG conjugated to horserad-
ish peroxidase (Cell Signaling, Beverly, MA, USA). The
membranes were washed again and transferred to freshly
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Billerica, MA, USA) and observed, recorded the signals
using the Gel Imagine System (Bio-Rad, Hercules, CA,
USA) or exposed to X-ray film.
Treatment with FOXO3a and RUNX3 small interfering
RNAs (siRNAs)
For the transfection procedure, cells were seeded in 6-well
or 96-well culture plates in RPMI 1640 medium containing
5% FBS (no antibodies), grown to 70% confluence, and
FOXO3a. RUNX3 and control siRNAs were transfected
using the lipofectamine 2000 reagent according to the
manufacturer’s instructions. Briefly, Lipofectamine 2000
was incubated with Opti-MEM medium (Invitrogen,
Carlsbad, CA, USA) for 5 min, mixed with siRNA (up to
50 nM), and incubated for 20 min at room temperature
before the mixture was added into the cells. After culturing
for up to 30 h, the cells were washed and resuspended in
fresh media in the presence or absence of baicalein for an
additional 24 h for all other experiments.
Electroporated transfection assays
The detailed procedure was based on the protocol from
the provider (Bio-Rad, Hercules, CA, USA). Briefly,
NSCLC cells (5x107 cells/mL) were transferred into
conical tubes and centrifuged at 1200 rpm for 5 min.
After centrifuging, the medium were removed and the
cells were washed with 1X PBS, and centrifuged again
at 1200 rpm for 5 min. Afterwards, the tubes were
added Bio-Rad Gene Pulser electroporation buffer.
After resuspending the cells, the desired N1-GFP or
FOXO3a-GFP plasmid DNA, kindly provided Frank
M. J. Jacobs (Rudolf Magnus Institute of Neuroscience,
Department of Pharmacology and Anatomy, University
Medical Center, Utrecht, Netherlands) and was reported
previously [26] and control (pCMV-6) or RUNX3 expres-
sion vector (RUNX3-pCMV6-AC-GFP, obtained from
OriGene Technologies, Inc. Rockville, MD, USA) at a final
concentration of 10 μg/mL were added and the electro-
poration plate were put in the MXcell plate chamber and
closed the lid. The electroporation conditions on the
plates to deliver 150 V/5 ms square wave were adjusted
until reaching the optimum. After electroporation was
completed, the cells were transferred to a tissue culture
plate. We typically transfer each 150 μL electroporation
sample to a 6-well tissue culture plate containing 2 mL
RPMI1640. Cells were incubated 48 h at 37°C, then
treated with baicalein for an additional 24 h.
Statistical analysis
All experiments were repeated a minimum of three
times. All data are expressed as mean ± SD. Differences
between groups were assessed by one-way ANOVA and
significance of difference between particular treatmentgroups was analyzed using Dunnett’s multiple comparison
tests or Bonferroni t-test using GraphPad Prism software
version 5.0 (GraphPad Software, Inc. La Jolla, CA , USA).
Asterisks showed in the figures indicate significant
differences of experimental groups in comparison with the
corresponding control condition. P-values <0.05 were
considered statistically significant.Results
Baicalein inhibited growth and induced apoptosis of
human NSCLC cells in a dose- and time-dependent
manner
We first detected the effect of baicalein on cell growth
in human NSCLC cells H1650 by MTT assay. As show
in Figure 1A, baicalein decreased the cell viability in a
dose- and time-dependent manner with maximal dose of
75 μM at 48 h treatment. Similar results were also observed
in other NSCLC cell lines (Figure 1B).
We also examined the effect of baicalein on apoptosis
in NSCLC cells. We found that H1650 cells treated with
increased concentrations of baicalein for 24 h resulted in
induction of apoptosis shown in the lower right (AB4)
quadrants of the histograms, which were counted as
“early” apoptotic cells (Figure 2A) as detected using the
Annexin V-FITC/PI stain Apoptotic Detection Kit. After
24 h of treatment, the baicalein-induced apoptotic rate
was greater than that in the non-treated control cells
(Figure 2A). Similar results were obtained in an additional
NSCLC cell line A549 cells (not shown). Meanwhile, the
effect of baicalein on apoptosis of H1650 and A549 cells
was also tested by measuring enzymatic caspase 3/7
activity. We observed the increased caspase 3/7 activity by
baicalein (Figure 2B). The above results indicated that
baicalein induced apoptosis in NSCLC cells.Baicalein increased the phosphorylation of ERK1/2 and
AMPKα in a time-dependent manner
MEK/ERK1/2 and AMPK signaling pathways were involved
in apoptosis and cell growth depending on the cell types
and stimulus. We showed that baicalein increased the phos-
phorylation of ERK1/2 and AMPKα in a time-dependent
manner in H1650 and A549 cells (Figure 3A-B). Note that
the expression of total ERK1/2 and AMPKα proteins had
no significant changes after baicalein treatment. The
reported data demonstrated a cross-talk between
MEK/ERK and AMPK pathways in other system [27,28].
In this study, we found that, while an AMPK inhibitor,
compound C, had little effect on influencing baicalein-
increased the phosphorylation of ERK1/2, the inhibitor of
MEK/ERK1/2 (PD98059), eliminated the baicalein-
induced phosphorylation of AMPKα (Figure 3C-D).
The latter was also observed using another selective
MEK/ERK1/2 inhibitor (U0126) (not shown). This result
A B
Figure 1 Baicalein inhibited growth of human lung carcinoma cells in a dose- and time-dependent manner. A, H1650 cells were treated with
increased concentrations of baicalein for up to 72 h to examine the cell viability by MTT assays as described in the Materials and Methods
section. B, NSCLC cell lines indicated were treated with baicalein (75 μM) for 48 h. The cell viability was determined using the MTT assay and
was expressed as percentage of control in the mean ± SD of three separate experiments. *indicates significant difference as compared to the
untreated control group (P < 0.05).
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stimulation of AMPK signaling in this process.
Baicalein increased protein expression of FOXO3a and
RUNX3 through ERK1/2 and AMPK pathways
In this study, we showed that baicalein increased
FOXO3a, a transcription factor with known anti-tumor
activity [29] and RUNX3, another tumor suppressor,
protein expression in a dose-dependent fashion in A549
and H1650 cells (Figure 4A). As expected, baicalein
increased FOXO3a and RUNX3 mRNA levels as
determined by qRT-PCR methods (Figure 4B) in A549
and H1650 cells. Next, we used specific inhibitors of
MEK/ERK1/2 and AMPK to pre-treated H1650 cells to
examine the role of these kinase in mediating the effect of
baicalein on induction of FOXO3a and RUNX3. As shown
in Figure 4C and D, the inhibitors of MEK/ERK1/2
(PD98059) and AMPK (compound C) either in part or
completely abolished baicalein-induced RUNX3 and
FOXO3a protein expression (Figure 4C-D). This result
showed that activation of MEK/ERK1/2 and AMPK was
involved in the baicalein-induced protein expression of
RUNX3 and FOXO3a.
Previously, we showed that baicalein induced apoptosis
in lung cancer cells. To further examine the role of
ERK1/2 and AMPK signaling pathways in this process,
we first treated cells with MEK/ERK1/2 and AMPK
inhibitors before exposing the cells to baicalein. As
shown in Figure 4D, compared with baicalein treated
alone, compound C blocked the baicalein-induced
caspase 3/7 activity, while PD98059 had no such effect.
This result indicated the role of activation of AMPK butnot MEK/ERK1/2 in mediating the effect of baicalein on
induction of apoptosis in NSCLC cells.
Induction of FOXO3a and RUNX3 involved in
baicalein-inhibited cell growth and apoptosis
Studies have shown that FOXO3a and RUNX3 regulated
cell growth and apoptosis. In this study, we further
tested the potential interaction of these molecules that
may affect the lung cancer cell growth. We found that
silencing of FOXO3a but not RUNX3 by siRNA
approaches significantly reversed the baicalein-inhibited
lung cancer cell growth (Figure 5A-B). Note that silencing
of FOXO3a and RUNX3 largely reduced the FOXO3a and
RUNX3 protein expression (Figure 5A-B, upper panel).
Interestingly, while silencing of FOXO3a had little
effect on influencing baicalein-induced RUNX3 protein
expression (Figure 5C), knockdown of RUNX3 significantly
attenuated the baicalein-induced protein expression of
FOXO3a (Figure 5D).
Overexpression of FOXO3a and RUNX3 restored cell
growth and attenuated apoptosis affected by baicalein
On the contrary, overexpression of FOXO3a restored
the effect of baicalein on cell growth in cells silencing of
endogenous FOXO3a gene by siRNA methods (Figure 6A).
In addition, it also enhanced the effect of baicalein on cell
growth inhibition (Figure 6B). Intriguingly, while exogenous
expression of RUNX3 had no effect on influencing
baicalein-inhibited cell growth (Figure 6C), silencing of
RUNX3 by siRNA significantly attenuated the effect
of baicalein on caspase 3/7 activity (Figure 6D). The
above findings indicated that the induction and potential
Figure 2 Baicalein induced apoptosis in NSCLC cells. A, H1650 cells were treated with increased concentrations of baicalein for 24 h. Afterwards,
cells were harvested for analysis of apoptosis using the Annexin V-FITC/PI Apoptosis Detection Kit as detailed in Materials and Methods section.
The AB3 quardrant (annexin V-/PI-), AB4 quadrant (annexin V+/PI-) and AB2 quadrant (annexin V+/PI+) of the histograms indicated the percentage of
normal cells, early apoptosis and late apoptosis, respectively. Data are expressed as a percentage of total cells. Values in bar graphs were given as the
mean ± SD from three independent experiments performed in triplicate. *indicates significant difference as compared to the untreated control group
(P < 0.05). B, Caspase 3/7 activity assay was performed on H1650 and A549 cells treated with or without baicalein for 48 h. Relative caspase 3/7 activity
is indicated as percentage of untreated control cells. Results represent those obtained in three experiments. *indicates significant difference as
compared to the untreated control group (P < 0.05). **indicates significant difference from baicalein treated alone (P < 0.05).
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uted to the baicalein-inhibited cell growth and -induced
apoptosis. This also implied that the inhibition of
proliferation could be in part an outcome of increased
cell apoptosis or vise versa. Moreover, we showed
that, while overexpression of FOXO3a had no further
effect on phosphorylation of AMPKα, exogenous expres-
sion of RUNX3 strengthened the effect of baicalein on
phosphorylation of ERK1/2 (Figure 6E) and induced
FOXO3a protein expression (Figure 6E).Discussion
Previous studies showed that baicalein could be considered
as a potential candidate for the treatment of human
cancers. However, the exact mechanisms involving in the
effect of baicalein on inhibition of cancer cell growth are
not fully understood. In this study, consistent with others
[7,8,30], baicalein showed significant cytotoxicity and
induced apoptosis in NSCLC cells. The concentrations of
baicalein used in this study and demonstrated to inhibit
lung cancer cell growth were consistent with other studies,
A B
C D
Figure 3 Baicalein increased the phosphorylation of ERK1/2 and AMPKα in a time-dependent manner. A-B, A549 and H1650 cells were treated
with baicalein (75 μM) in the indicated times, and cell lysate was harvested and the expression of the phosphorylated or total protein of ERK1/2,
AMPKα were measured by Western blot analysis using corresponding antibodies. GAPDH was used as loading control. C-D, H1650 cells were
treated with PD98059 (10 μM) (C) or compound C (C.C, 5 μM) (D) for 2 h before exposure of the cells to baicalein (BA, 75 μM) for an additional
24 h. Afterwards, the expression of p-ERK1/2 and p-AMPKα protein and their total forms was detected by Western blot. The bar graphs
represented the densitometry results of p-ERK or AMPKα /GAPDH as mean ± SD of at least three separate experiments. *indicates significant
difference from untreated control cells (P < 0.05). **indicates significant difference from baicalein treated alone (P < 0.05).
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cell growth and induction of apoptosis at physiological
doses [9,10,30].
Several signaling pathways and potential targets (genes
or/and proteins) that involved in the overall responses of
baicalein in inhibition of growth and induction of apoptosis
in cancer cells have been reported [9,10,31]. Consistentwith this, our results demonstrated that, in addition to
ERK1/2, activation of AMPKα signaling was also implicated
in the effect of baicalein on induction of FOXO3a and
RUNX3 expression. AMPK is the central component of
protein kinase cascade that plays a key role in the regula-
tion of energy control. Activated AMPK induces catabolic





Figure 4 Baicalein increased protein levels of FOXO3a and RUNX3 through ERK1/2 and AMPK pathways. A, H1650 and A549 cells were exposed
to increased concentration of baicalein for 24 h. Afterwards, the expression of FOXO3a and RUNX3 protein were detected by Western blot. B,
H1650 and A549 cells were exposed to baicalein for 24 h. Afterwards, the expression of FOXO3a and RUNX3 mRNAs was detected by real-time
RT-PCR method as described in the Materials and Methods section. C-D, H1650 cells were treated with PD98059 (10 μM) (C) or compound C
(5 μM) (D) for 2 h before exposure of the cells to baicalein (75 μM) for an additional 24 h. Afterwards, the expression of FOXO3a and RUNX3
protein were detected by Western blot using antibodies against FOXO3a and RUNX3. The bar graphs represent the mean ± SD of RUNX3/GAPDH
and FOXO3a/GAPDH of three independent experiments. E, H1650 cells were treated with PD98059 (10 μM) or compound C (5 μM) for 2 h before
exposure of the cells to baicalein (75 μM) for an additional 24 h. Afterwards, the cells were collected and processed for analysis of apoptosis as
determined by caspase 3/7 activity assays. Results represent those obtained in three experiments. *indicates significant difference as compared to
the untreated control group (P < 0.05). **indicates significant difference from baicalein treated alone (P < 0.05).
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suppressor [32,33]. Our results suggested that activation of
MEK/ERK1/2 led to stimulation of AMPKα signaling and
the reciprocal interaction of MEK/ERK1/2 and AMPKα
signaling pathways contributed to the overall responses of
baicalein in the control of lung cancer cell proliferation.The crosstalk between MEK/ERK1/2 and AMPKα signaling
in mediating the physiopathological responses of cancer cell
survival have been reported in other studies [27,28],
demonstrating the critical roles of the complicated signaling
networks in regulation of gene expression and cancer cell




Figure 5 Induction of FOXO3a and RUNX3 mediated baicalein-inhibited cell growth. A-B, H1650 cells were transfected with control or FOXO3a, or
RUNX3 siRNAs with lipofectamine 2000 reagent for 24 h, followed by exposure the cells to baicalein (BA, 75 μM) for an additional 24 h. Afterwards,
the cells proliferation was detected using MTT assays. The expression of FOXO3a and RUNX3 protein was determined by Western blot. The bar graphs
represent the mean ± SD of RUNX3/GAPDH and FOXO3a/GAPDH of three independent experiments. The insert blots represent the protein expression
of FOXO3a and RUNX3. C-D, H1650 cells were transfected with control or FOXO3a or RUNX3 siRNAs (50 nM each) for 24 h before exposing the cell to
baicalein (BA) for an additional 24 h. Afterwards, the expression of FOXO3a and RUNX3 protein was determined by Western blot. *indicates significant
difference from untreated control cells **indicates significant difference from baicalein treated alone (P < 0.05).
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Figure 6 Overexpression of FOXO3a and RUNX3 restored cell growth and attenuated apoptosis affected by baicalein. A, H1650 cells were
transfected with control or FOXO3a siRNA for 30 h, followed by control or FOXO3a expression vectors for up to 24 h before exposure of the cells
to baicalein for an additional 24 h. Afterwards, cell growth was determined by MTT assays. The upper insert panel represents blots of expression
of FOXO3a protein detected by Western blot. B-C, H1650 cells were transfected with control or FOXO3a, or RUNX3 expression vectors for 24 h
before exposing the cells to baicalein for an additional 24 h. Afterwards, cell viability were detected by MTT assays. Insert blots were FOXO3a and
RUNX3 protein expression. D, H1650 cells were transfected with control or RUNX3 siRNA for 30 h before exposing the cells to baicalein for an
additional 24 h. Afterwards, the cells were processed for analysis of apoptosis as determined by caspase 3/7 activity assays. Data are expressed as
a percentage of total cells. Values in bar graphs were given as the mean ± SD from three independent experiments. *indicates significant
difference as compared to the untreated control group (P<0.05). **indicates significant difference from baicalein treated alone (P<0.05). E, H1650
cells were transfected with control or FOXO3a, or RUNX3 expression vectors for 24 h before exposing the cells to baicalein for an additional 2 h.
Afterwards, The expression of FOXO3a and RUNX3 protein, phosphorylation of AMPKα and ERK1/2 were determined by Western blot. F, The
graph shows that baicalein inhibits growth and induces apoptosis of lung cancer cells through AMPKα- and ERK1/2-mediated increase in RUNX3
and FOXO3a protein expression. Overexpression of RUNX3 strengthens baicalein-induced phosphorylation of ERK1/2 and induces expression of
FOXO3a. The crosstalk between AMPKα and ERK1/2, and the reciprocal incorporation of FOXO3a and RUNX3 converge on the overall anti-cancer
responses of baicalein.
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kinases, are needed to confirm the loss of MEK/ERK1/2 in
preventing the activation of AMPK. Of note, recent studies
suggested dual roles of AMPK played in cancer biology
depending on environmental context [34]. We believed that
the truly insight into the role of AMPK in suppressing
tumor growth needs to be well characterized.
Our study suggested that increased FOXO3a and
RUNX3 expression were involved in the inhibition of
NSCLC cell proliferation. FOXO3a is a member of the
FOXO transcription factor family, which modulate the
expression of genes involved in cell cycle arrest, apoptosis,
autophagy, and other cellular processes. We previously
demonstrated that induction of FOXO3a was involved in
the berberine- and curcumin-, two bioactive components
extracted from TCM herbs, inhibited growth and -induced
apoptosis in NSCLC and nasopharyngeal carcinoma cells
[17,19]. Consistent with this, others also showed similar
results indicating the tumor suppressor role of this
transcriptional factor [35,36]; this implied that FOXO3a
represents an attractive therapeutic target in the chemopre-
vention and possibly in inhibition of progression of human
cancers. In addition, we for the first time demonstrated the
inhibitory effect of baicalein on RUNX3, another tumor
suppressor whose reduced expression may play an
important role in the development and progression of
several cancer types including lung [23,37,38]. Inactivation
of RUNX3 was a crucial early event in the occurrence and
development of lung malignancy [23,39,40], and upregula-
tion of RUNX3 inhibited lung cancer cell growth [41].
Study implicated a central role of RUNX3 downregulation
in lung adenocarcinoma occurrence that may be inde-
pendent of other well-known cancer-related pathways and
suggested potential diagnostic implications [22]. This also
highlighted a critical role of this tumor suppressor in the
treatment of lung cancer. Our results indicated that
RUNX3 could be an upstream of FOXO3a and that silen-
cing and overexpression of RUNX3 could regulate the
FOXO3a expression, this together with the data from
silencing of RUNX3 in refraining apoptosis suggested that
the expression and interplay between these two molecules
played an important role in influencing the overall
responses of baicalein. One study showed that RUNX3
could interact with FOXO3a to induce the expression of
pro-apoptotic proteins, thereby triggering apoptosis in
gastric cancer cells [42]. Nevertheless, the detailed
mechanism of this interplay in mediating anti-tumor
activity of baicalein required to be further elucidated.
Intriguingly, our results also suggested the important
roles of ERK1/2 and AMPKα signaling pathways in
mediating the effect of baicalein on induction of FOXO3a
and RUNX3 proteins. Reports from ours and other
studies demonstrated that activation of MEK/ERK1/2
or/and AMPK contributed to increase in FOXO3a protein,decrease in cancer cell growth, and other functions in
several cell systems [17,43-46]. Novel baicalein derivatives
found to activate AMPK in various tumor cell types [45];
moreover, one report showed that, by activation of
AMPKα-mediated multiple downstream intracellular
signaling pathways, baicalein could protect mice from
metabolic syndrome induced by a high-fat diet [46]. Of
note, inactivation ERK1/2 signaling was involved in the
induction of FOXO3a and RUNX3 in other studies [47,48].
The discrepancy remains unclear; different stimuli, cell
lines used and environmental contexts may be responsible
for this, which need to be determined in the future studies.
Moreover, there were no reports demonstrating the link of
AMPK signaling and RUNX3 expression. We believed that
our findings provided the novel insight into the connection
between AMPKα signaling and expression of RUNX3
affected by baicalein, and also highlighted the tumor
suppressor role of AMPKα and RUNX3 that were
involved in the anti-tumor effect of baicalein. Furthermore,
we for the first time demonstrated a positive feedback
regulation of ERK1/2 signaling by RUNX3, in turn, this
would further enhance the anti-tumor efficacy of baicalein.
This, together with the data showing that silencing of
FOXO3a and RUNX3 reversed the effect of baicalein on
cell proliferation and apoptosis, confirmed the critical roles
of FOXO3a and RUNX3 played in this process. It is
possible that inhibition of proliferation can be in part
a consequence of increased apoptosis or vise versa.
We predicted that FOXO3a and RUNX3 could be
valuable prognostic markers as well as potential molecular
targets for lung cancer. Note that, while baicalein has been
shown to increase FOXO3a and RUNX3, whether this
was due to a transcriptional (e.g., mRNA expression)
or posttranscriptional regulation (e.g., protein stability)
required to be determined.
Conclusion
Collectively, our results show that baicalein inhibits
growth and induces apoptosis of NSCLC cells through
MEK/ERK1/2- and AMPKα-mediated increase in FOXO3a
and RUNX3 proteins, respectively. Overexpression of
RUNX3 increases FOXO3a and strengthens baicalein-
induced phosphorylation of ERK1/2. The activation and
cross-talk of AMPKα and MEK/ERK1/2 signaling path-
ways, and reciprocal interplay of RUNX3 and FOXO3a
expression contribute to the overall responses of baicalein,
which unveils a novel molecular mechanism by which
baicalein controls human lung cancer cell growth
(Figure 6F).
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